Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.

Samouëlian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, Provencher DM, Mes-Masson AM.

Cancer Chemother Pharmacol. 2004 Dec;54(6):497-504. Epub 2004 Jul 16.

PMID:
15258697
[PubMed - indexed for MEDLINE]
2.

Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Manderson EN, Mes-Masson AM, Novak J, Lee PD, Provencher D, Hudson TJ, Tonin PN.

Genome Res. 2002 Jan;12(1):112-21.

PMID:
11779836
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines.

Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN.

Oncogene. 2003 Mar 13;22(10):1568-79.

PMID:
12629520
[PubMed - indexed for MEDLINE]
4.

Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation.

Fan S, Twu NF, Wang JA, Yuan RQ, Andres J, Goldberg ID, Rosen EM.

Int J Cancer. 1998 Aug 12;77(4):600-9.

PMID:
9679765
[PubMed - indexed for MEDLINE]
5.

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.

Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM.

Oncogene. 2001 Oct 4;20(45):6617-26.

PMID:
11641787
[PubMed - indexed for MEDLINE]
Free Article
6.

Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.

Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, Allen HJ, DiCioccio RA.

Cancer Genet Cytogenet. 1999 Jul 15;112(2):105-18.

PMID:
10686936
[PubMed - indexed for MEDLINE]
7.

Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.

Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN.

Mol Carcinog. 2008 Jan;47(1):56-65.

PMID:
17620309
[PubMed - indexed for MEDLINE]
8.

Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells.

Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N.

Eur J Cancer. 2000 Sep;36(14):1863-8.

PMID:
10974635
[PubMed - indexed for MEDLINE]
9.

Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts.

Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N.

Eur J Cancer. 2000 Sep;36(14):1869-75.

PMID:
10974636
[PubMed - indexed for MEDLINE]
10.

Comparison of endogenous TP53 genomic status with clonogenicity and different modes of cell death after X irradiation.

Lu-Hesselmann J, Abend M, van Beuningen D.

Radiat Res. 2004 Jan;161(1):39-47.

PMID:
14680398
[PubMed - indexed for MEDLINE]
11.

Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.

Britten RA, Perdue S, Eshpeter A, Merriam D.

Oncol Rep. 2000 Jul-Aug;7(4):821-5.

PMID:
10854551
[PubMed - indexed for MEDLINE]
12.

Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.

Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, Tonin PN.

Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.

PMID:
19509545
[PubMed - indexed for MEDLINE]
13.

A useful cell system for studying the regulation of 17HSD/KSR type 2 activity and expression in ovarian epithelial cancer.

Provost PR, Lima PH, Tremblay Y, Blomquist CH.

J Steroid Biochem Mol Biol. 2010 Oct;122(4):295-301. doi: 10.1016/j.jsbmb.2010.06.008. Epub 2010 Jun 17.

PMID:
20600897
[PubMed - indexed for MEDLINE]
14.

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.

Cody NA, Zietarska M, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN.

BMC Med Genomics. 2008 Aug 7;1:34. doi: 10.1186/1755-8794-1-34.

PMID:
18687136
[PubMed]
Free PMC Article
15.

Mutations of TP53 do not correlate with the sensitivity to paclitaxel--a study using 27 gynaecological cancer cell lines.

Rantanen V, Engblom P, Raitanen M, Hietanen S, Haarala M, Grénman S, Syrjänen S.

Eur J Cancer. 2002 Sep;38(13):1783-91.

PMID:
12175696
[PubMed - indexed for MEDLINE]
16.
17.

Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Mürdter TE, Aulitzky WE.

BMC Cancer. 2008 Dec 11;8:364. doi: 10.1186/1471-2407-8-364.

PMID:
19077243
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Induction of accelerated senescence by gamma radiation in human solid tumor-derived cell lines expressing wild-type TP53.

Mirzayans R, Scott A, Cameron M, Murray D.

Radiat Res. 2005 Jan;163(1):53-62.

PMID:
15606307
[PubMed - indexed for MEDLINE]
19.

Radiosensitivity patterns of four human ovarian cancer cell lines in vitro.

Petru E, Sevin BU, Gottlieb C.

Gynecol Oncol. 1997 Mar;64(3):490-2.

PMID:
9062157
[PubMed - indexed for MEDLINE]
20.

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Markl ID, Jones PA.

Cancer Res. 1998 Dec 1;58(23):5348-53.

PMID:
9850064
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk